Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eisai

New Alzheimer's drug faces uncertain regulatory path

The FDA will soon decide whether to approve Eisai's experimental drug lecanemab.

Axios

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

WEKU

New Alzheimer’s drug hailed as 'beginning of the end' in quest for treatment

Clinical results suggest that the disease progression can by slowed by 27%

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Alzheimer's drug sparks hot debate over benefits as risks like brain bleeding emerge

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Tribune News Service

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment

Lecanemab was found to slow decline in patients’ memory and thinking.

The Independent UK

Drug slows Alzheimer's but can it make a real difference?

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

The Independent UK

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

Axios

Read news from The Economist, FT, and more,
with one subscription

New Alzheimer's drug that slows cognitive decline could be available next year

People who are prescribed the drug will need regular MRI scans to check for brain swelling or bleeding

Wales Online

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

The Conversation

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

Tribune News Service

‘Historic moment’: Drug slows cognitive decline in Alzheimer’s

It's being widely reported that an experimental drug has slowed the cognitive decline and brain damage in Alzheimer's patients.

The New Daily

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

The Guardian - UK

Success of experimental Alzheimer’s drug hailed as ‘historic moment’

Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

Wales Online

Drug shown to slow memory decline in Alzheimer's patients in 'historic' breakthrough

Alzheimer's Research UK said this is the first later-stage trial of an Alzheimer's drug 'in a generation' to successfully slow cognitive decline

Daily Record

Alzheimer's drug is world's first shown to slow symptoms in 'historic' breakthrough

The success of an experimental drug offers new hope to people affected by the cruel disease.

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

‘Historic’ breakthrough as dementia drug shown to slow cognitive decline

Lecanemab found to slow decline in participants’ memory and thinking caused by the brain-wasting disease by 27 per cent

Daily Mirror

World's first EVER drug shown to work against Alzheimer's developed by scientists

Scientists say the development of the only drug to work against Alzheimer’s is a 'historic moment' - with regulators expected to approve the groundbreaking drug by the New Year

Wales Online

Major breakthrough for dementia and Alzheimer's as drug found to reduce decline

Alzheimer’s Research UK said the finding was a “historic moment for dementia research”

The Independent UK

‘Major breakthrough’ as dementia drug found to ‘slow cognitive decline’

The new clinical trial found that there was a significant reduction in the decline in memory and thinking usually seen in early-stage patients.

Benzinga

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Tribune News Service

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

346 stories

Biogen

206 stories

University College London

189 stories

Alzheimer Research UK

Alzheimer Association

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.